nordic-nanovector-big

New CMO and Executive Management Team member for Nordic Nanovector

pharmafile | November 15, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Nordic Nanovector has recruited a new chief medical officer (CMO) and Executive Management Team member with the appointment of Dr Lisa Rojkjaer.

In her new role, Dr Rojkjaer will take charge of the firm’s clinical development strategy and assist the company in exploring avenues to expand its haematological cancer therapy pipeline. A board-certified haematologist, she brings over 15 years of experience to the role, having worked formerly as the global clinical program head, Oncology Global Development at Novartis. She has also held positions at Novo Nordisk and Molecular Partners.

“I am very pleased to welcome Lisa to the team,” CEO Luigi Costa remarked. “She brings on board strong expertise in clinical development of novel cancer treatments, particularly in the field of haematology. Lisa’s knowledge and leadership will be key to the development of Betalutin® as well as to support the growth of Nordic Nanovector’s promising pipeline.”

Advertisement

Dr Rojkjaer said of her appointment: “I am delighted to join Nordic Nanovector at this exciting time in its development. The company’s lead candidate Betalutin® is demonstrating in clinical studies its potential to become an important new therapy for the treatment of NHL patients. Its technology is also providing multiple exciting new pipeline opportunities. I look forward to working with the management team and contributing to the future growth of the company.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content